Watson ships generic Pravachol
Watson Pharmaceuticals, a USA-based specialty pharmaceutical company, says that under a distribution agreement with US drug major Bristol-Myers Squibb, the company has initiated shipments of pravastatin sodium tablets, the authorized generic version of Bristol-Myers Squibb's cholesterol-lowering agent, Pravachol, in 10mg, 20mg and 40mg strengths.
The drug is indicated, along with diet, to reduce the risk of both first heart attack in patients with elevated cholesterol and recurrent heart attack or stroke in patients with heart disease, when diet and exercise are not enough. Watson stated that, for 2005, Pravachol had sales of approximately $1.7 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze